Oxygenation impairment in patients with acute aortic dissection is associated with disorders of coagulation and fibrinolysis: a prospective observational study

Abstract

Background

Stanford type-A acute aortic dissection (AAD) is typically accompanied by oxygenation impairment before surgery. In addition, inflammation, coagulation and fibrinolysis also impair blood oxygenation. However, our understanding of the concentration of these factors in bronchoalveolar lavage fluid (BALF) has not been reported. The objective of the study was to investigate the impact of preoperative acute lung injury (ALI) on postoperative oxygenation impairment and to explore the effect of coagulation and fibrinolysis in blood and BALF.

Methods

This investigation utilized a prospective observational study design, which was registered at www.clinicaltrials.gov (identifier NCT01894334). The study included 53 patients undergoing surgery for Stanford type-A AAD at an academic hospital in China between October 2013 and July 2014. Preoperative ALI was identified according to the oxygenation index calculated by the PaO₂/FiO₂ ratio. The subjects were divided into the ALI group (oxygenation index ≤300 mmHg) or the control group (oxygenation index >300 mmHg). The primary outcome was patient oxygenation index, while secondary outcomes were concentrations of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and plasminogen activator inhibitor-1 (PAI-1) in serum and BALF.

Results

The incidence of preoperative ALI for Stanford type-A AAD patients was 41.5%. Stanford type-A AAD patients with preoperative ALI had a lower postoperative oxygenation index (104.6±31.7 vs. 248.7±48.0 mmHg, P<0.001), higher concentrations of TF in serum and BALF (F=133.67, P<0.001; F=68.14, P<0.001), higher concentrations of TFPI in serum and BALF (F=31.98, P<0.001; F=45.58, P<0.001), and higher concentrations of PAI-1 in serum and BALF (F=213.88, P<0.001; F=107.95, P<0.001) when compared with those without preoperative ALI. Type-A AAD patients also showed a greater loss of blood (1,524±458 vs. 1,175±327 mL, P=0.040), longer mechanical ventilation time in the ICU (27.24±8.37 vs. 17.33±7.36 h, P<0.001), longer total stay in the ICU (42.27±10.85 vs. 33.45±9.05 h, P=0.002), and longer total hospital stay (17.77±5.00 vs. 13.48±3.97 days, P=0.001). Multivariate linear regression analysis indicated that preoperative PAI-1 in BALF, and TF in both serum and BALF were significantly associated with preoperative oxygenation impairment in patients with Stanford type-A AAD.

Conclusions

Preoperative ALI caused more serious postoperative oxygenation impairment for Stanford type-A AAD, and coagulation and fibrinolysis appear to play critical roles in this process. Preoperative PAI-1 in BALF and TF in both serum and BALF were significant factors related to the occurrence of preoperative oxygenation impairment for Stanford type-A AAD.

Introduction

Despite recent advancements in medical technology, acute aortic dissection (AAD) is an age-dependent, clinically serious, urgent, and life-threatening cardiovascular disease associated with high morbidity and mortality due to potentially fatal complications (1). The mortality rate of AAD has been reported to be as high as 1–2%/h from the onset of symptoms, and the mortality rate is 33% within the first 24 h, 50% within the first 48 h, 75% within 2 weeks, and 90% after three months for patients who have not been treated promptly (2).

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are still life-threatening diseases in critically ill patients and are common complications during perioperative management and can seriously impact patient prognosis (3). The current overall mortality rate of ARDS is still more than 40% (4), and recent reports suggest that more than half of AAD patients will experience varying degrees of hypoxemia (5-7).

Prior investigations have indicated that inflammation (8-10), coagulation, and fibrinolysis (11-17) are associated with AAD pathogenesis and AAD-associated mortality. However, studies on the role of coagulation and fibrinolysis in AAD-induced ALI are still lacking. To the best of our knowledge, the correlation between the biomarkers of coagulation and fibrinolysis in bronchoalveolar lavage fluid (BALF) and AAD-induced ALI has not been reported.

Therefore, the purpose of this investigation was to assess the impact of preoperative ALI on postoperative oxygenation impairment and explore the correlation between preoperative ALI and tissue factor (TF), tissue factor pathway inhibitor (TFPI), and plasminogen activator inhibitor-1 (PAI-1) in blood and BALF. We also sought to clarify the associated factors of preoperative oxygenation impairment.

Methods

Design and participants

The investigation was a single-center, observational, prospective study, and was registered at www.clinicaltrials.gov (Identifier: NCT01894334; Date: June 8, 2013). A total of 53 Stanford type-A AAD patients were enrolled from October 2013 to July 2014 in Beijing Anzhen Hospital, an academic hospital in China. Inclusion criteria included patients aged 18–70 years old, those previously diagnosed Stanford type-A AAD, an onset time of fewer than two weeks, and patients scheduled for emergency surgery. Exclusion criteria included serious cardiopulmonary disease, chronic diseases of the liver, renal, and nervous system, coagulation disease, inflammatory disease, recent use of anti-inflammatory and anti-coagulant medication, and rejection of consent. Based on the presence or lack of ALI before surgery, the subjects were divided into the ALI group (group A, 22 subjects) or the control group (group C, 31 subjects). The primary outcome was patient oxygenation index and the secondary outcomes were concentrations of TF, TFPI, and PAI-1 in serum and BALF. All methods in this study were performed in accordance with relevant guidelines and regulations and were approved by the Clinical Research Ethics Committee of Beijing Anzhen Hospital (Identifier: 2012013). Written informed consent was obtained from all subjects before inclusion in this study.

Definitions

All subjects underwent contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) to confirm the diagnosis of Stanford type-A AAD according to the Stanford classification (18). All subjects underwent arterial blood gas analysis and chest radiograph for the diagnosis of ALI and ARDS, based on the combination of the criteria published by the American European Consensus Conference in 1994 (19), and the “Berlin criteria” published by the European Society of Intensive Care Medicine in 2012 (20). These criteria include the presence of risk factors, acute onset, oxygenation index (oxygen arterial pressure/oxygen inspired fraction, PaO₂/FiO₂) ≤300 mmHg for ALI, oxygenation index ≤200 mmHg for ARDS regardless of ventilator settings, appearance of bilateral pulmonary infiltration on chest radiograph, and oxygenation impairment not fully explained by cardiac failure.

Anesthesia and surgery

All subjects underwent established monitoring of radial artery pressure, dorsalis pedis artery pressure, and central venous pressure before surgery. The anesthesia protocol was standardized and included etomidate 0.3 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 1–3 µg/kg for anesthesia induction, and midazolam, propofol, pancuronium, and sufentanil for anesthesia maintenance. The Bispectral index was maintained between 40 and 60 during surgery.

All surgical procedures were performed with the patient under general anesthesia, cardiopulmonary bypass (CPB), deep hypothermic circulatory arrest (DHCA), and selective cerebral perfusion using a modified elephant trunk technique named after Dr. Li-Zhong Sun. “Sun’s surgery” refers to a total arch replacement using a graft with four branches and implantation of a special stented endovascular graft.

Indicators and methods

The oxygenation index was calculated using the formula PaO₂/FiO₂. Blood was collected at four-time points: after hospital admission (T₁), before surgery (T₂), at the end of surgery (T₃), and 12 h after surgery (T₄). BALF was collected at T₂ and T₃. Briefly, the right main bronchus was located, and a bronchial occluder was inserted by fiberoptic bronchoscopy for BALF collection. Rapid infusion of 3 mL/kg sterile saline (37 °C) was performed, followed by the reclamation of lavage fluid using 50–100 mmHg negative pressure aspiration. The recovery rate was controlled at 40–60%, and then the recovered liquid was immediately filtered with double sterile gauze to remove mucus and to record the total amount for each sample. Finally, each sample was immediately centrifuged (1,500 ×g, 10 min) and stored in a refrigerator at −80 °C for later analysis. TF, TFPI, and PAI-1 were assayed using an ELISA kit (Lanyuan Biotechnology Co., Ltd, Shanghai, China). All ELISA assays were tested twice, and the mean value was used for analysis.

Statistical analysis

All statistical analyses were performed using IBM SPSS software version 23.0 (IBM Corporation, Armonk, NY, USA). Continuous variables are expressed as mean ± standard deviation and were analyzed with a Student’s t test for normally distributed data, and a Mann-Whitney U-test for data that did not exhibit a normal distribution. The categorical variables were expressed as percentages and analyzed with a Chi-squared test. Odds ratio (OR) and 95% confidence intervals (CI) were tested by a cross-table. Repeated-measures analysis of variance (ANOVA) was used to evaluate differences in parametric variables. The analyzed factors were phases (T₁, T₂, T₃, and T₄) and groups (group A and group C). The within-subjects factor was phase, and the between- subjects factor was group. If the effect of group and phase was significant, the simple main effects were tested. Mauchly’s test of sphericity was performed. If the sphericity assumption was violated, the degrees of freedom were corrected using the Greenhouse-Geisser epsilon. The Bonferroni post hoc test was used for pairwise comparisons. Variables showing a linear correlation in scatter plots with preoperative oxygenation index (T₁) and having a P value <0.10 in Pearson linear correlation analysis were put into a multivariate logistic regression analysis model to identify associated factors for preoperative oxygenation impairment. A “Stepwise” methodology was employed and included variables in our multiple linear regression models that increased the probability of F by at least 0.05 and excluded variables if they increased F by less than 0.1. A two-tailed P value <0.05 was considered statistically significant.

Results

Subject demographics

There were no significant differences in subject demographics (Table 1). Study participants included 43 males and 10 females, aged from 23 to 66 years, with an average age of 46±10 years.

Table 1. Subject demographics [$\overline{x}\pm s$, n (%)].

Subject demographics	Group A (n=22)	Group C (n=31)	t (χ2)	P
Age (years)	47.4±9.3	43.7±11.2	1.313	0.195
Gender: male, n (%)	18 (81.8)	25 (80.6)	0.139	0.709
Height (cm)	1.70±0.69	1.73±0.86	−1.252	0.216
Weight (kg)	73.2±11.6	76.8±15.8	−0.971	0.336
BMI (kg/m2)	25.1±3.2	25.6±4.4	−0.418	0.675
Onset time (days)	3.6±1.2	3.8±1.4	−0.470	0.641
Onset time ≤2 days, n (%)	3 (13.6)	3 (9.7)	0.201	0.654
Aortic diameter (mm)	52.0±7.4	50.1±4.7	1.076	0.287
Aortic intramural hematoma, n (%)	2 (9.1)	6 (19.4)	3.358	0.067
Partially thrombosed false lumen, n (%)	7 (31.8)	8 (25.8)	0.547	0.459
Significant aortic regurgitation, n (%)	3 (13.6)	5 (16.1)	1.127	0.444
Preoperative SBP (mmHg)	121±21	122±23	−0.240	0.811
Preoperative DBP (mmHg)	57±11	53±9	1.724	0.091
Preoperative HR (beats/min)	76±12	69±14	1.930	0.059
Preoperative LVEF (%)	58±7	57±4	0.819	0.416
Preoperative LVEDD (mm)	52±5	50±6	0.946	0.349
Preoperative NT-proBNP (pg/mL)	47.41±19.92	36.08±14.79	1.549	0.128
Preoperative WBC (109/L)	10.19±5.95	9.27±3.84	0.687	0.495
Preoperative CRP (mg/L)	37.26±9.22	32.42±8.93	1.920	0.060
Preoperative SCr (ìmol/L)	87.83±38.08	94.92±25.27	−0.815	0.419
Preoperative D-dimer (ìg/L)	2,922±1,559	2,216±1,235	1.838	0.072
History of hypertension, n (%)	13 (59.1)	17 (54.8)	3.616	0.057
History of DM, n (%)	6 (27.3)	6 (19.4)	0.139	0.709

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NT-proBNP, N terminal pro B type natriuretic peptide; WBC, white blood cells; CRP, C-reaction protein; SCr, serum creatinine; DM, diabetes mellitus.

Subject perioperative data

Subject perioperative data are presented in Table 2. There were significant differences in intraoperative blood loss (1,524±458 versus 1,175±327 mL, P=0.040), mechanic ventilation time in the ICU (27.24±8.37 versus 17.33±7.36 h, P<0.001), stay in ICU (42.27±10.85 versus 33.45±9.05 h, P=0.002), and hospital stay (17.77±5.00 versus 13.48±3.97 days, P=0.001).

Table 2. Subject perioperative data [$\overline{x}\pm s$, n (%)].

Subject perioperative data	Group A (n=22)	Group C (n=31)	t (χ2)	P
Fluids (mL)	2,361±1,131	2,229±674	0.461	0.647
Red cells (mL)	3.80±1.25	3.33±1.42	0.634	0.531
Plasma (mL)	696±258	536±221	1.643	0.108
Blood loss (mL)	1,524±458	1,175±327	2.111	0.040
Urine (mL)	1,429±406	1,546±512	−0.443	0.660
Surgery time (hours)	8.48±3.33	8.25±2.92	0.267	0.790
CPB time (hours)	3.49±0.76	3.63±0.85	−0.588	0.559
Circulatory arrest time (hours)	2.11±0.56	2.16±0.58	−0.314	0.755
Lowest rectal temperature during CPB (°C)	24.1±0.3	24.3±0.3	−0.467	0.642
CABG in surgery, n (%)	1 (4.5)	2 (6.5)	0.088	0.767
Postoperative cerebral complications, n (%)	0 (0)	1 (3.2)	1.232	0.267
Postoperative NT-proBNP (pg/mL)	92.28±42.70	99.79±43.03	−0.635	0.528
Abnormal postoperative NT-proBNP, n (%)	2 (9.1)	2 (6.5)	0.039	0.844
Mechanic ventilation time in ICU (hours)	27.24±8.37	17.33±7.36	4.528	<0.001
Stay in ICU (hours)	42.27±10.85	33.45±9.05	3.218	0.002
Hospital stay (days)	17.77±5.00	13.48±3.97	3.475	0.001
In-hospital mortality, n (%)	2 (9.1)	3 (9.7)	0.005	0.943

CPB, cardiopulmonary bypass; CABG, coronary artery bypass graft; NT-proBNP, N terminal pro B type natriuretic peptide.

Oxygenation

The incidence of preoperative ALI for Stanford type-A AAD patients was 41.5% (22/53). Oxygenation index in group A and group C at T₁, T₂, T₃, and T₄ were 189.0±65.4 versus 366.3±56.8; 193.2±62.0 versus 361.5±46.2; 130.8±40.5 versus 299.6±48.4; and 104.6±31.7 versus 248.7±48.0 mmHg, respectively. Student’s t-test showed the oxygenation index in group A was lower than group C at each time point (P<0.001), and the oxygenation index of T₃ andT₄ was lower than T₁ in both groups (P<0.001, Table 3).

Table 3. Oxygenation index ($\overline{x}\pm s$) (mmHg).

Time	Group A (n=22)	Group C (n=31)	t	P
T1	189.0±65.4	366.3±56.8	−10.413	<0.001
T2	193.2±62.0	361.5±46.2	−10.992	<0.001
T3	130.8±40.5a	299.6±48.4a	−13.818	<0.001
T4	104.6±31.7b	248.7±48.0b	−10.924	<0.001

^a, oxygenation index at T₃ compared with T₁, P<0.001; ^b, oxygenation index at T₄ compared with T₁, P<0.001.

Consecutive variables of oxygenation index at T₄ were converted into binary variables representing ARDS and non-ARDS for assessing incidence. ARDS incidences were 86.36% (19/22) in group A and 25.81% (8/31) in group C. OR and 95% CI were calculated, OR =8.77 (95% CI, 2.14–35.96). Pearson Chi-square was also performed (Chi-square =10.62, P=0.001).

The concentrations of TF, TFPI, and PAI-1

The impacts of different groups and phases on the concentrations of TF, TFPI, and PAI-1 are presented in Table 4, and the profile plot shows the estimated mean values of TF, TFPI, and PAI-1 (Figure 1).

Table 4. The concentrations of TF, TFPI, and PAI-1 ($\overline{x}\pm s$).

Variables	Group	T1	T2	T3	T4	Sum	F	P
TF (ng/mL)
Serum	A	11.16±4.55	9.36±3.90	24.46±6.67	32.24±8.00	19.30±11.21	96.09	<0.001
	C	3.63±1.39	3.05±1.56	14.01±2.80	15.46±5.80	9.04±6.65	91.61	<0.001
	Sum	7.75±5.13	6.50±4.39	19.73±7.42	24.64±10.97	14.60±10.76	134.23a	<0.001a
	t	8.45	7.97	7.66	8.57	133.67a	(F=8.57, P<0.001)b
	P	<0.001	<0.001	<0.001	<0.001	<0.001a
BALF	A	–	5.53±2.61	6.51±2.69	–	6.02±2.67	2.00	0.163
	C	–	2.18±0.98	2.60±1.37	–	2.39±1.20	1.53	0.222
	Sum	–	4.01±2.64	4.74±2.93	–	4.62±2.86	3.32a	0.074a
	t	–	6.38	3.69	–	68.14a	(F=0.52, P=0.474)b
	P	–	<0.001	0.001	–	<0.001a
TFPI (ng/mL)
Serum	A	148.06±26.61	151.19±27.55	216.29±65.84	226.04±73.39	185.40±63.47	17.87	<0.001
	C	103.67±15.59	105.65±14.45	170.53±45.97	186.42±37.58	141.57±48.70	44.87	<0.001
	Sum	127.96±31.41	130.57±32.02	195.57±61.62	208.10±62.62	165.55±61.17	58.97a	<0.001a
	t	4.81	5.14	2.49	3.33	31.98a	(F=0.07, P=0.944)b
	P	<0.001	<0.001	0.016	0.002	<0.001a
BALF	A	–	67.12±16.90	66.65±21.41	–	66.89±19.12	0.01	0.927
	C	–	36.89±8.66	40.96±14.16	–	38.93±11.80	1.45	0.235
	Sum	–	53.43±20.44	55.02±22.41	–	54.22±21.36	1.04a	0.313a
	t	–	3.72	2.44	–	45.58a	(F=1.65, P=0.205)b
	P	–	<0.001	0.018	–	<0.001 a
PAI-1 (pg/mL)
Serum	A	0.88±0.27	0.94±0.23	1.82±0.25	1.87±0.29	1.38±0.54	123.76	<0.001
	C	0.54±0.13	0.56±0.13	1.03±0.23	1.08±0.26	0.80±0.32	53.01	<0.001
	Sum	0.73±0.28	0.76± 0.27	1.46±0.46	1.51±0.48	1.17±0.54	197.81a	<0.001a
	t	5.66	5.38	6.70	6.70	213.88 a	(F=17.79, P=0.944)b
	P	<0.001	<0.001	<0.001	<0.001	<0.001 a
BALF	A	–	5.87±1.87	8.04±2.14	–	6.95±2.28	17.01	<0.001
	C	–	1.95±0.79	3.93±1.11	–	3.11±1.27	35.36	<0.001
	Sum	–	4.09±2.46	6.24±2.65	–	5.21±2.69	83.11a	<0.001a
	t	–	10.21	3.81	–	107.95a	(F=0.18, P=0.674)b
	P	–	<0.001	<0.001	–	<0.001a

^a, F statistic and P value of the main effect; ^b, F statistic and P value of crossover effect. TF, tissue factor; TFPI, tissue factor pathway inhibitor; PAI-1, plasminogen activator inhibitor-1; BALF, bronchoalveolar lavage fluid.

Figure 1.

Profile plots show the estimated mean of concentrations of TF, TFPI, and PAI-1. (A) The estimated mean of concentrations of TF in serum. (B) The estimated mean of concentrations of TF in BALF. (C) The estimated mean of concentrations of TFPI in serum. (D) The estimated mean of concentrations of TFPI in BALF. (E) The estimated mean of concentrations of PAI-1 in serum. (F) The estimated mean of concentrations of PAI-1 in BALF. TF, tissue factor; TFPI, tissue factor pathway inhibitor; PAI-1, plasminogen activator inhibitor-1; BALF, bronchoalveolar lavage fluid.

Serum concentrations of TF were significantly different across phases (F=134.23; P<0.001), and in both group A (F=96.09; P<0.001) and group C (F=91.61; P<0.001). They gradually increased and peaked at T₄ in both groups. Serum concentrations of TF in group A were significantly higher than group C overall (F=133.67; P<0.001), and in all phases. There was a significant interaction between phase and group (F=8.57; P<0.001). BALF concentrations of TF had no difference among phases overall (F=3.32; P=0.074), and in both group A (F=2.00; P=0.163) and group C (F=1.53; P=0.222). BALF concentrations of TF in group A were significantly higher than group C overall (F=68.14; P<0.001), and in both phases. There was no interaction between phase and group (F=0.52; P=0.474).

Serum concentrations of TFPI showed significant differences among phases overall (F=58.97; P<0.001), and in both group A (F=17.87; P<0.001) and group C (F=44.87; P<0.001). They gradually increased and peaked at T₄ in both groups. Serum concentrations of TFPI in group A were significantly higher than group C overall (F=31.98; P<0.001), and in all phases. There was no interaction between phase and group (F=0.07; P=0.944). BALF concentrations of TFPI had no difference among phases overall (F=1.04; P=0.313), and in both group A (F=0.01; P=0.927) and group C (F=1.45; P=0.235). BALF concentrations of TFPI in group A were significantly higher than group C overall (F=45.58; P<0.001), and in both phases. There was no interaction between phase and group (F=1.65; P=0.205).

Serum concentrations of PAI-1 had significant differences among phases overall (F=197.81; P<0.001), and in both group A (F=123.76; P<0.001) and group C (F=53.01; P<0.001). They gradually increased and peaked at T₄ in both groups. Serum concentrations of PAI-1 in group A were significantly higher than group C overall (F=213.88; P<0.001), and in all phases. There was no interaction between phase and group (F=17.79; P=0.944). BALF concentrations of PAI-1 at T₃ were significantly higher than T₂ overall (F=83.11; P<0.001), and in both group A (F=17.01; P<0.001) and group C (F=35.36; P<0.001). BALF concentrations of PAI-1 in group A were significantly higher than group C overall (F=107.95; P<0.001), and in both phases. There was no interaction between phase and group (F=0.18; P=0.674).

The associated factors of preoperative oxygenation impairment

Multivariate linear regression analysis was used to evaluate which variables were associated with preoperative oxygenation impairment (Table 5). Serum TF (T₁), serum TFPI (T₁), serum PAI-1 (T₁), BALF TF (T₂), BALF TFPI (T₂), and BALF PAI-1 (T₂) had a linear correlation with preoperative oxygenation index (T₁). We then put them into our multivariate linear regression analysis model. The adjusted R² of our model is 0.786 with the R² =0.811, indicating that the linear regression explained 78.6% of the variance in the data. The F-test was significant (AVONA: F_6,46 =32.808, P<0.001), suggesting that the model explains a significant amount of the variance.

Table 5. The variables that have correlations with oxygenation index (T₁) in Pearson linear correlation.

Variables	Pearson correlation	P
Serum TF (T1)	−0.813	<0.001
Serum TFPI (T1)	−0.734	<0.001
Serum PAI-1 (T1)	−0.455	0.001
BALF TF (T2)	−0.556	<0.001
BALF TFPI (T2)	−0.645	<0.001
BALF PAI-1 (T2)	−0.805	<0.001

TF, tissue factor; TFPI, tissue factor pathway inhibitor; PAI-1, plasminogen activator inhibitor-1; BALF, bronchoalveolar lavage fluid.

BALF PAI-1 (T₂), serum TF (T₁), and BALF TF (T₂) were associated factors in our multivariate linear regression analysis model. The equation utilized was “Y =528.154−11.229 [BALF PAI-1 (T₂)] –7.084 [serum TF (T₁)] –7.818 [BALF TF (T₂)]” (Table 6).

Table 6. Coefficients in multiple linear regression.

Variables	Unstandardized coefficients			Standardized coefficients	t	P	Collinearity statistics
	B	Std. error		Beta			Tolerance	VIF
Constant	528.154	31.971		–	16.520	<0.001	–	–
BALF PAI-1 (T2)	−11.229	5.499		−0.255	−2.042	0.047	0.263	3.798
Serum TF (T1)	−7.084	2.688		−0.337	−2.635	0.011	0.252	3.963
BALF TF (T2)	−7.818	2.980		−0.191	−2.623	0.012	0.779	1.284

BALF, bronchoalveolar lavage fluid; PAI-1, plasminogen activator inhibitor-1; TF, tissue factor.

Discussion

Despite advancements in diagnostic and perioperative management modalities (21), AAD is associated with rapid progress course, complex treatment course, high complication incidence, and high morbidity and mortality rates (2).

The present investigation demonstrates that 41.5% of Stanford type-A AAD patients had suffered ALI before surgery. Sugano et al. (22) published a similar report claiming that 51% of patients evidence oxygenation impairment within 24 h after onset of AAD, while a cross-sectional clinical study from our institution (23) revealed that 53.8% of the patients undergoing Stanford type-A AAD surgery had preoperative hypoxemia. In addition, we found that if patients had suffered preoperative ALI, their oxygenation index would be lower, and they were more likely to develop to ARDS and had longer mechanic ventilation time in ICU longer stay in the ICU and longer hospital stay after surgery. Sheng et al. (7) also suggested that a preoperative PaO₂/FiO₂ ≤300 mmHg was an independent risk factor of hypoxemia after surgery for Stanford type-A AAD. Increased postoperative oxygenation impairment may occur due to an increased inflammatory response that is associated with the magnitude of the operative injury and the procedure (24-28). Therefore, taking measures to improve ALI earlier is crucial for the prognosis of Stanford type-A AAD patients.

Also, the current surgical treatment strategy for Stanford type-A AAD patients in our institution may be reevaluated and improved for the patients with preoperative oxygenation impairment. For example, the surgery time, CPB time, and circulatory arrest time should be shortened as much as possible by taking all feasible measures, and if the condition affords, a straightforward supra-coronary ascending aortic replacement should be performed instead of the total arch procedure to reduce the surgical trauma and CPB-induced inflammation.

Although a correlation between the degree of ALI in patients with AAD and inflammatory response has been demonstrated previously (29,30), the pathogenesis of AAD in conjunction with ALI, and the correlation of coagulation and fibrinolysis with ALI remains unclear. The meta-analysis by Shimony et al. (31) suggested that D-dimer is highly sensitive in the diagnosis of aortic dissection, and D-dimer <500 µg/L may assist in the exclusion of aortic dissection. The study of MacLaren et al. (17) also showed that intrapulmonary microthrombosis and fibrin deposition are two critical mechanisms associated with ALI due to the imbalance of coagulation and fibrinolysis.

The results of this investigation suggest that Stanford type-A AAD patients with preoperative ALI have persistently higher levels of TF and TFPI in serum and BALF. Importantly, TF in serum and BALF was measured before surgery and (T₁) is an associated factor of preoperative oxygenation impairment for Stanford type-A AAD. TF is a 47-kD, membrane-bound protein and is a potent agonist of exogenous clotting cascade reactions. Under normal circumstances, the concentration of TF in blood is low, and the normal TF-dependent blood coagulation plays a major role in hemostasis after tissue injury (32). However, under abnormal circumstances, the abnormal TF-dependent coagulation activation can be the basis of some diseases including acute myocardial infarction and ALI (33,34). We inferred that when aortic dissection appears, the host defense response activates lymphocytes and macrophages, and endothelial cells release a large number of inflammatory cytokines that activate the transcription factor of neutrophils and macrophages, which will cause TF to be activated and released. Excessive TF in blood will be one of the main causes of preoperative oxygenation impairment.

In contrast, TFPI is composed of 276 amino acid residues and controls the natural anticoagulant protein in the priming phase of coagulation, which has a specific inhibitory effect on the TF pathway. We found that the concentrations of TFPI in serum and BALF were much lower than TF (concentration of TFPI was about 1% of that of TF), which caused that the TFPI pool in endothelial cells was exhausted and there was not enough existing TFPI to neutralize TF and reverse TF-induced activation of coagulation (35). Therefore, TFPI may play a relatively weak role in the regulation of coagulation and inflammation, but it cannot change the hypercoagulable state and has a limited effect on oxygenation for Stanford type-A AAD patients.

PAI-1 is the most important inhibitor of plasminogen activator and is an important component of the plasminogen/plasmin system. This investigation showed that Stanford type-A AAD patients with preoperative ALI have persistently higher levels of PAI-1, and the BALF PAI-1 at T₂ was an associated factor of preoperative oxygenation impairment for Stanford type-A AAD. These results suggest that, in Stanford type-A AAD patients, the effect of PAI-1 on oxygenation may be achieved through the pulmonary alveoli instead of the systemic circulation. These results also explain the state of systemic fibrinolysis in AAD patients and the state of fibrinolysis inhibition caused by the increase of PAI-1. Acute fibrinolysis appeared in the early stage of AAD, which is associated with the increased plasminogen activator-induced by the activation of the host defense response (36). Following an early fibrinolysis reaction, there was a rapid and sustained production of PAI-1. However, the increase of PAI-1 in the blood is likely insufficient to completely “neutralize” the continuous increase of plasminogen activator-induced by the massive production of inflammatory cytokines and TF, which are still dominant in the blood of AAD patients. In addition, Montes et al. (37) reported that activated protein C could inhibit PAI-1, which may be another reason that fibrinolysis remains in the blood. We also found the concentration of PAI-1 in BALF was much higher than in the serum. This result was consistent with the findings of Prabhakaran et al. that illustrated the concentration of PAI-1in pulmonary edema fluid was higher than in blood for ALI patients, suggesting that there are alveolar origins for PAI-1, such as alveolar macrophages, alveolar type-2 epithelial cells, and fibroblasts (38-40). Moreover, local pulmonary medication is more efficacious than systemic medication (41). Therefore, PAI-1 may be an important indicator and cause of perioperative ALI for Stanford type-A AAD patients, but its effect is more likely in pulmonary alveoli, which further suggests that the choice of administration route is also crucial to the effectiveness of prophylaxis and treatment for ALI.

Therefore, moderate activation and disorder of coagulation and fibrinolysis in the pulmonary circulation can help the alveolar epithelial cells and repair of endothelial cell damage, while also reducing permeability. Unfortunately, excessive alveolar fibrin deposition will activate neutrophils and fibroblasts, release more inflammatory cytokines, increase vascular endothelial permeability, further promote thrombin generation and fibrin deposition, reduce alveolar surface activity substance production, and result in alveolar collapse and the occurrence of hypoxemia (13).

Despite its prospective design, this study was limited primarily by its small (n=53), single-center based population. We also cannot exclude the possibility that other factors may have impacted systemic oxygenation. Future investigations will examine other factors, such as key cytokines and chemokines in BALF, that may cause poor oxygenation. Furthermore, we did not collect BALF at T₁ and T₄ due to ethical and patient safety considerations. As a result, data that may be of value are lacking. Finally, this was an observational study that lacked an intervention. Despite the presence of these limitations, to our knowledge, this was the first investigation that exanimated TF, TFPI, and PAI-1 both in serum and in BALF, and compared them for Stanford type-A AAD patients with preoperative ALI and those without preoperative ALI. In addition, we found for the first time that preoperative BALF PAI-1 (T₂), serum TF (T₁), and BALF TF (T₂) were associated factors of preoperative oxygenation impairment for Stanford type-A AAD. In the future, we will expand the sample size and give appropriate interventions, to further explore the mechanism of ALI, especially in coagulation and fibrinolysis. These studies will then provide a clinical basis for early intervention and may improve the prognosis of AAD patients.

In conclusion, preoperative ALI is associated with lower postoperative oxygenation index, higher postoperative ARDS incidence, longer mechanical ventilation time in the ICU, a longer stay in the ICU, longer total hospital stay, and persistently higher levels of TF, TFPI, and PAI-1 for Stanford type-A AAD patients. Preoperative BALF PAI-1, serum TF, and BALF TF are associated factors of preoperative oxygenation impairment for Stanford type-A AAD. Thus, activation and disorder of coagulation and fibrinolysis may help explain the association of the occurrence and progressive development of ALI with Stanford type-A AAD.

Ethical Statement: All methods in this study were performed in accordance with relevant guidelines and regulations and were approved by the Clinical Research Ethics Committee of Beijing Anzhen Hospital (Identifier: 2012013). Written informed consent was obtained from all subjects before inclusion in this study.